[Form 4] Edwards Lifesciences Corp Insider Trading Activity
Edwards Lifesciences (EW) insider sale disclosed on Form 4. Reporting person Daveen Chopra, listed as an officer (CVP, TMTT), sold 2,500 shares of Edwards Lifesciences common stock on 08/25/2025 at a weighted average price of $81.946 per share. After the sale the filing reports 30,996 shares beneficially owned by the reporting person, held directly. The filing states the reported sale was executed in multiple trades at prices ranging from $81.9401 to $81.9500 and that the weighted average price is provided; the filer offers to supply detailed trade-by-trade information upon request. The form notes it reflects changes in beneficial ownership only and does not list other securities the reporting person may own.
Vendita interna di Edwards Lifesciences (EW) comunicata nel Form 4. La persona che ha effettuato la segnalazione, Daveen Chopra, indicata come dirigente (CVP, TMTT), ha venduto 2.500 azioni ordinarie di Edwards Lifesciences il 25/08/2025 a un prezzo medio ponderato di $81,946 per azione. Dopo la vendita il documento riporta che la persona che segnala detiene 30.996 azioni in propriet脿 effettiva, detenute direttamente. La comunicazione precisa che la vendita 猫 stata eseguita in operazioni multiple a prezzi compresi tra $81,9401 e $81,9500 e che viene fornito il prezzo medio ponderato; il dichiarante si offre di fornire su richiesta i dettagli delle singole operazioni. Il modulo indica che riflette solo variazioni nella propriet脿 effettiva e non elenca altri titoli che la persona che segnala potrebbe possedere.
Venta de insider de Edwards Lifesciences (EW) divulgada en el Formulario 4. La persona que presenta el informe, Daveen Chopra, indicada como directivo (CVP, TMTT), vendi贸 2.500 acciones ordinarias de Edwards Lifesciences el 25/08/2025 a un precio medio ponderado de $81,946 por acci贸n. Tras la venta, el informe indica que la persona informante posee 30.996 acciones en propiedad beneficiaria, mantenidas directamente. El documento se帽ala que la venta se ejecut贸 en varias operaciones a precios que oscilaron entre $81,9401 y $81,9500 y que se proporciona el precio medio ponderado; el declarante ofrece facilitar, si se solicita, la informaci贸n detallada operaci贸n por operaci贸n. El formulario aclara que refleja 煤nicamente cambios en la propiedad beneficiaria y no enumera otros valores que la persona informante pueda poseer.
Edwards Lifesciences (EW) 雮措秬鞛� 毵り皝鞚� Form 4鞐� 瓿奠嫓霅橃棃鞀惦媹雼�. 鞁犼碃鞚� Daveen Chopra電� 鞛勳洂(CVP, TMTT)鞙茧 旮办灛霅橃柎 鞛堨溂氅� 2025-08-25鞐� Edwards Lifesciences 氤错喌欤� 2,500欤茧ゼ 欤茧嫻 臧�欷戫弶攴� $81.946鞐� 毵る弰頄堨姷雼堧嫟. 毵る弰 頉� 鞝滌稖靹滊電� 鞁犼碃鞚胳澊 歆侅爲 氤挫湢頃� 30,996欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� 頃措嫻 毵り皝鞚� 臧�瓴� 氩旍渼 $81.9401鞐愳劀 $81.9500 靷澊鞚� 鞐煬 瓯半灅搿� 鞁ろ枆霅橃棃瓿� 臧�欷戫弶攴犼皜瓴╈澊 鞝滉车霅橃棃鞚岇潉 氇呾嫓頃橂┌, 鞁犾箔 鞁� 瓯半灅氤� 靸侅劯 雮挫棴鞚� 鞝滉车頃橁矤雼り碃 頃╇媹雼�. 鞚� 鞏戩嫕鞚� 鞁れ鞝� 靻岇湢甓岇潣 氤�瓴诫鞚� 氚橃榿頃橂┌ 鞁犼碃鞚胳澊 氤挫湢頃� 靾� 鞛堧姅 雼るジ 歃濌秾鞚� 旮办灛頃橃 鞎婋姅雼り碃 鞝來榾 鞛堨姷雼堧嫟.
Vente d'initi茅 d'Edwards Lifesciences (EW) divulgu茅e sur le Formulaire 4. La personne d茅clarante, Daveen Chopra, indiqu茅e comme dirigeant (CVP, TMTT), a vendu 2 500 actions ordinaires d'Edwards Lifesciences le 25/08/2025 脿 un prix moyen pond茅r茅 de 81,946 $ par action. Apr猫s la vente, le d茅p么t indique que la personne d茅clarante d茅tient 30 996 actions d茅tenues de mani猫re b茅n茅ficiaire, d茅tenues directement. Le dossier pr茅cise que la vente a 茅t茅 ex茅cut茅e en plusieurs transactions 脿 des prix allant de 81,9401 $ 脿 81,9500 $ et que le prix moyen pond茅r茅 est fourni ; le d茅clarant propose de fournir, sur demande, les d茅tails transaction par transaction. Le formulaire note qu'il ne refl猫te que les changements de propri茅t茅 b茅n茅ficiaire et n'茅num猫re pas d'autres titres que la personne d茅clarante pourrait poss茅der.
Insider-Verkauf von Edwards Lifesciences (EW) im Formular 4 offengelegt. Die meldepflichtige Person Daveen Chopra, aufgef眉hrt als Officer (CVP, TMTT), verkaufte am 25.08.2025 2.500 Stammaktien von Edwards Lifesciences zu einem gewichteten Durchschnittspreis von $81,946 je Aktie. Nach dem Verkauf meldet die Einreichung, dass die meldepflichtige Person 30.996 Aktien wirtschaftlich besitzt, die direkt gehalten werden. Die Einreichung gibt an, dass der Verkauf in mehreren Trades zu Preisen zwischen $81,9401 und $81,9500 ausgef眉hrt wurde und der gewichtete Durchschnittspreis angegeben ist; der Einreicher bietet an, auf Anfrage detaillierte trade鈥慴y鈥憈rade Angaben zu liefern. Das Formular weist darauf hin, dass nur 脛nderungen der wirtschaftlichen Eigent眉merschaft dargestellt werden und andere vom Melder gehaltene Wertpapiere nicht aufgef眉hrt sind.
- Complete disclosure of sale quantity, weighted-average price, and post-transaction ownership
- Execution range disclosed (prices from $81.9401 to $81.9500) with offer to provide trade-level details upon request
- None.
Insights
TL;DR: Officer sale of 2,500 EW shares reduces direct holdings to 30,996; transaction appears routine and not materially large.
The sale on 08/25/2025 of 2,500 shares at a weighted average of $81.946 is a clear, single-day reduction of direct holdings by the reporting officer. The filing discloses execution in multiple trades within a narrow price band, and the filer commits to provide transaction details if requested. There is no indication in this Form 4 of derivative transactions, changes to compensation arrangements, or other concurrent disclosures that would suggest a material corporate event. Given the absolute size disclosed and absence of additional context, this appears to be a routine insider sale rather than a company-specific signal.
TL;DR: The disclosure meets Section 16 requirements and provides the required weighted-average price note; no governance red flags visible.
The Form 4 identifies the reporting person as an officer (CVP, TMTT) and correctly reports the sale quantity, post-transaction direct ownership, and price disclosure including the range of trade prices. The remarks explicitly state the form covers only beneficial ownership changes and not other holdings. From a governance perspective, the filing is complete for the transaction reported and includes an agent signature. The form does not show any suspicious timing or related-party transactions within this document.
Vendita interna di Edwards Lifesciences (EW) comunicata nel Form 4. La persona che ha effettuato la segnalazione, Daveen Chopra, indicata come dirigente (CVP, TMTT), ha venduto 2.500 azioni ordinarie di Edwards Lifesciences il 25/08/2025 a un prezzo medio ponderato di $81,946 per azione. Dopo la vendita il documento riporta che la persona che segnala detiene 30.996 azioni in propriet脿 effettiva, detenute direttamente. La comunicazione precisa che la vendita 猫 stata eseguita in operazioni multiple a prezzi compresi tra $81,9401 e $81,9500 e che viene fornito il prezzo medio ponderato; il dichiarante si offre di fornire su richiesta i dettagli delle singole operazioni. Il modulo indica che riflette solo variazioni nella propriet脿 effettiva e non elenca altri titoli che la persona che segnala potrebbe possedere.
Venta de insider de Edwards Lifesciences (EW) divulgada en el Formulario 4. La persona que presenta el informe, Daveen Chopra, indicada como directivo (CVP, TMTT), vendi贸 2.500 acciones ordinarias de Edwards Lifesciences el 25/08/2025 a un precio medio ponderado de $81,946 por acci贸n. Tras la venta, el informe indica que la persona informante posee 30.996 acciones en propiedad beneficiaria, mantenidas directamente. El documento se帽ala que la venta se ejecut贸 en varias operaciones a precios que oscilaron entre $81,9401 y $81,9500 y que se proporciona el precio medio ponderado; el declarante ofrece facilitar, si se solicita, la informaci贸n detallada operaci贸n por operaci贸n. El formulario aclara que refleja 煤nicamente cambios en la propiedad beneficiaria y no enumera otros valores que la persona informante pueda poseer.
Edwards Lifesciences (EW) 雮措秬鞛� 毵り皝鞚� Form 4鞐� 瓿奠嫓霅橃棃鞀惦媹雼�. 鞁犼碃鞚� Daveen Chopra電� 鞛勳洂(CVP, TMTT)鞙茧 旮办灛霅橃柎 鞛堨溂氅� 2025-08-25鞐� Edwards Lifesciences 氤错喌欤� 2,500欤茧ゼ 欤茧嫻 臧�欷戫弶攴� $81.946鞐� 毵る弰頄堨姷雼堧嫟. 毵る弰 頉� 鞝滌稖靹滊電� 鞁犼碃鞚胳澊 歆侅爲 氤挫湢頃� 30,996欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� 頃措嫻 毵り皝鞚� 臧�瓴� 氩旍渼 $81.9401鞐愳劀 $81.9500 靷澊鞚� 鞐煬 瓯半灅搿� 鞁ろ枆霅橃棃瓿� 臧�欷戫弶攴犼皜瓴╈澊 鞝滉车霅橃棃鞚岇潉 氇呾嫓頃橂┌, 鞁犾箔 鞁� 瓯半灅氤� 靸侅劯 雮挫棴鞚� 鞝滉车頃橁矤雼り碃 頃╇媹雼�. 鞚� 鞏戩嫕鞚� 鞁れ鞝� 靻岇湢甓岇潣 氤�瓴诫鞚� 氚橃榿頃橂┌ 鞁犼碃鞚胳澊 氤挫湢頃� 靾� 鞛堧姅 雼るジ 歃濌秾鞚� 旮办灛頃橃 鞎婋姅雼り碃 鞝來榾 鞛堨姷雼堧嫟.
Vente d'initi茅 d'Edwards Lifesciences (EW) divulgu茅e sur le Formulaire 4. La personne d茅clarante, Daveen Chopra, indiqu茅e comme dirigeant (CVP, TMTT), a vendu 2 500 actions ordinaires d'Edwards Lifesciences le 25/08/2025 脿 un prix moyen pond茅r茅 de 81,946 $ par action. Apr猫s la vente, le d茅p么t indique que la personne d茅clarante d茅tient 30 996 actions d茅tenues de mani猫re b茅n茅ficiaire, d茅tenues directement. Le dossier pr茅cise que la vente a 茅t茅 ex茅cut茅e en plusieurs transactions 脿 des prix allant de 81,9401 $ 脿 81,9500 $ et que le prix moyen pond茅r茅 est fourni ; le d茅clarant propose de fournir, sur demande, les d茅tails transaction par transaction. Le formulaire note qu'il ne refl猫te que les changements de propri茅t茅 b茅n茅ficiaire et n'茅num猫re pas d'autres titres que la personne d茅clarante pourrait poss茅der.
Insider-Verkauf von Edwards Lifesciences (EW) im Formular 4 offengelegt. Die meldepflichtige Person Daveen Chopra, aufgef眉hrt als Officer (CVP, TMTT), verkaufte am 25.08.2025 2.500 Stammaktien von Edwards Lifesciences zu einem gewichteten Durchschnittspreis von $81,946 je Aktie. Nach dem Verkauf meldet die Einreichung, dass die meldepflichtige Person 30.996 Aktien wirtschaftlich besitzt, die direkt gehalten werden. Die Einreichung gibt an, dass der Verkauf in mehreren Trades zu Preisen zwischen $81,9401 und $81,9500 ausgef眉hrt wurde und der gewichtete Durchschnittspreis angegeben ist; der Einreicher bietet an, auf Anfrage detaillierte trade鈥慴y鈥憈rade Angaben zu liefern. Das Formular weist darauf hin, dass nur 脛nderungen der wirtschaftlichen Eigent眉merschaft dargestellt werden und andere vom Melder gehaltene Wertpapiere nicht aufgef眉hrt sind.
FAQ
What did Daveen Chopra sell in the Edwards Lifesciences (EW) Form 4?
At what price were the EW shares sold according to the Form 4?
How many EW shares does the reporting person own after the transaction?
What is the reporting person鈥檚 role at Edwards Lifesciences per the filing?
Does the Form 4 disclose any derivative transactions or other securities?
